Clinical Research

A study that analyzed patient outcomes in coronary artery bypass grafting (CABG) in veterans showed outcomes for on-pump and off-pump procedures over 10 years to be similar. Photo by Jim Lennon

CABG bests PCI for multivessel CAD, large new study confirms

"The singular message to the public is that the optimal treatment for multivessel coronary artery disease—to improve not only long-term survival but also lower your risk of complications—is coronary artery bypass surgery," one specialist said in a statement. 

Thumbnail

High hopes still afloat as promising Alzheimer’s drug loses bid for accelerated approval

The FDA has declined to accelerate approval of Eli Lilly’s highly anticipated Alzheimer’s drug, but the reason for the rejection may presage a forthcoming thumbs-up.

Thumbnail

An updated look at surgically repairing the mitral valve due to mitral regurgitation

A team of cardiologists and cardiac surgeons collaborated on the new analysis, reviewing data from more than 50,000 patients and developing a new risk model for clinicians.  

Thumbnail

MRI and mass spectrometry imaging to play key role in Alzheimer's research

By combining MSI results with whole-brain MRI exams, researchers are hoping to gain insight into the development of Alzheimer’s disease on a molecular level. 

covid-19 coronavirus

PCSK9 inhibition may reduce risk of death for patients with severe COVID-19

JACC pilot study suggests possible benefits for patients with severe cases of COVID-19 infection. 

Thumbnail

Intermittent fasting not associated with long-term weight loss, according to new 6-year analysis

Reducing total calorie intake and minimizing large meals, on the other hand, were both linked to improved weight loss. The study followed participants for an average of 6.3 years. 

Deep learning slashes real-world MRI scan times

Accelerated MRI with AI image reconstruction nearly halved orthopedic scan times while maintaining or even improving image quality in a newly published prospective study. 

Peter Libby, MD, a cardiovascular medicine specialist, Brigham and Women’s Hospital, and Mallinckrodt Professor of Medicine, Harvard Medical School, explains the take aways from the PROMINENT trial using pemafibrate to lower cardiovascular risks. The trial, presented at the American Heart Association (AHA) 2022 meeting, did not show reduction in the incidence of cardiovascular events among those who received pemafibrate than among those who received placebo. #AHA #AHA22

VIDEO: Pemafibrate does not lower cardiovascular risks in the PROMINENT trial

Peter Libby, MD, a cardiovascular medicine specialist with Brigham and Women’s Hospital and Harvard Medical School, explained some key takeaways from the PROMINENT trial.